Published in Genetics and Environmental Business Week, January 18th, 2007
Using proprietary genome-wide microarray technology, the company was able to quickly identify a suite of novel biomarkers in a panel consisting of normal and cancerous breast tissues. In a second independent biomarker validation panel of more than 200 normal and cancerous breast tissues, over 50 biomarkers demonstrated significant diagnostic potential, the most promising of which presented 90% sensitivity and 96%...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.